New in #JCO Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial #MCC #openaccess #oncsky ascopubs.org/doi/10.1200/...
Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial | Journal of Cli...
PURPOSETo investigate whether intermittent treatment after an induction phase of first-line
schedule of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus panitumumab (PAN)
prevents or delays the...
ascopubs.org
November 24, 2024 at 6:05 PM
New in #JCO Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial #MCC #openaccess #oncsky ascopubs.org/doi/10.1200/...
Sotorasib Plus Panitumumab Provides Effective Targeted Therapy Option in KRAS G12C+ mCRC
@cityofhope.bsky.social #crcsm #oncology #MedEd
www.onclive.com/view/sotoras...
@cityofhope.bsky.social #crcsm #oncology #MedEd
www.onclive.com/view/sotoras...
Sotorasib Plus Panitumumab Provides Effective Targeted Therapy Option in KRAS G12C+ mCRC
Marwan G. Fakih, MD, discusses the FDA approval of sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.
www.onclive.com
February 11, 2025 at 7:10 PM
Sotorasib Plus Panitumumab Provides Effective Targeted Therapy Option in KRAS G12C+ mCRC
@cityofhope.bsky.social #crcsm #oncology #MedEd
www.onclive.com/view/sotoras...
@cityofhope.bsky.social #crcsm #oncology #MedEd
www.onclive.com/view/sotoras...
Thanks 🙏🏻 to @oncodaily.bsky.social to highlight the results of #IMPROVE trial Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic #CRC #GIonc #OncSky oncodaily.com/blog/panitum...
Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC - OncoDaily
Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC / Akhil Santhosh, Alberto Sobrero, Alessandra Leone, Alfonso De
oncodaily.com
January 18, 2025 at 10:11 PM
Thanks 🙏🏻 to @oncodaily.bsky.social to highlight the results of #IMPROVE trial Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic #CRC #GIonc #OncSky oncodaily.com/blog/panitum...
Analysis from the AGEO group: Switching Cetuximab to Panitumumab During Encorafenib Therapy in BRAF V600E–Mutated mCRC
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AGEO #mCRC
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AGEO #mCRC
Analysis from the AGEO group: Switching Cetuximab to Panitumumab During Encorafenib Therapy in BRAF V600E–Mutated mCRC - OncoDaily
Analysis from the AGEO group: Switching Cetuximab to Panitumumab During Encorafenib Therapy in BRAF V600E–Mutated mCRC / AGEO multicenter study, cancer,
oncodaily.com
December 23, 2025 at 10:10 PM
#IMPROVE trial #Intermittent (I) or #Continuous (C) Panitumumab+FOLFIRI for First-Line Treatment of RAS/BRAF WT Metastatic Colorectal Cancer #oncsky #JCO
✅ Endpoint met
👉mPFS 11.2(C)vs17.5 months(I)
👉NO detrimental effect on OS
👉DCR 94.2%(C)vs91%(I)
👉Reduced toxicity
ascopubs.org/doi/pdf/10.1...
✅ Endpoint met
👉mPFS 11.2(C)vs17.5 months(I)
👉NO detrimental effect on OS
👉DCR 94.2%(C)vs91%(I)
👉Reduced toxicity
ascopubs.org/doi/pdf/10.1...
December 6, 2024 at 8:29 AM
#IMPROVE trial #Intermittent (I) or #Continuous (C) Panitumumab+FOLFIRI for First-Line Treatment of RAS/BRAF WT Metastatic Colorectal Cancer #oncsky #JCO
✅ Endpoint met
👉mPFS 11.2(C)vs17.5 months(I)
👉NO detrimental effect on OS
👉DCR 94.2%(C)vs91%(I)
👉Reduced toxicity
ascopubs.org/doi/pdf/10.1...
✅ Endpoint met
👉mPFS 11.2(C)vs17.5 months(I)
👉NO detrimental effect on OS
👉DCR 94.2%(C)vs91%(I)
👉Reduced toxicity
ascopubs.org/doi/pdf/10.1...
As a survivor (*knock on wood*) because of monoclonal antibodies (panitumumab ftw!), I have much love for the work they've done developing these treatments so far. Seeing something like this therapeutic become available gives me major hope!
August 3, 2023 at 5:16 PM
As a survivor (*knock on wood*) because of monoclonal antibodies (panitumumab ftw!), I have much love for the work they've done developing these treatments so far. Seeing something like this therapeutic become available gives me major hope!
Intermittent treatment with FOLFIRI plus panitumumab reduced toxicity and maintained effectiveness in colorectal cancer patients.
by Avallone A, Giuliani F (...) Budillon A et 23 al. in J Clin Oncol #MedSky
📖 read the article: https://ascopubs.org/doi/10.1200/JCO.24.00979
by Avallone A, Giuliani F (...) Budillon A et 23 al. in J Clin Oncol #MedSky
📖 read the article: https://ascopubs.org/doi/10.1200/JCO.24.00979
December 1, 2024 at 6:35 PM
Intermittent treatment with FOLFIRI plus panitumumab reduced toxicity and maintained effectiveness in colorectal cancer patients.
by Avallone A, Giuliani F (...) Budillon A et 23 al. in J Clin Oncol #MedSky
📖 read the article: https://ascopubs.org/doi/10.1200/JCO.24.00979
by Avallone A, Giuliani F (...) Budillon A et 23 al. in J Clin Oncol #MedSky
📖 read the article: https://ascopubs.org/doi/10.1200/JCO.24.00979
📣Updated recommendations for third & further lines treatment of advanced CRC
@Annals_Oncology
doi.org/10.1016/j.an...
🔎 ESMO mCRC Living Guideline
👉Fruquintinib recommended
👉Cetuximab–adagrasib recommended in mKRAS G12C
👉Panitumumab–sotorasib not yet approved
@myESMO
@Annals_Oncology
doi.org/10.1016/j.an...
🔎 ESMO mCRC Living Guideline
👉Fruquintinib recommended
👉Cetuximab–adagrasib recommended in mKRAS G12C
👉Panitumumab–sotorasib not yet approved
@myESMO
December 5, 2024 at 12:19 PM
📣Updated recommendations for third & further lines treatment of advanced CRC
@Annals_Oncology
doi.org/10.1016/j.an...
🔎 ESMO mCRC Living Guideline
👉Fruquintinib recommended
👉Cetuximab–adagrasib recommended in mKRAS G12C
👉Panitumumab–sotorasib not yet approved
@myESMO
@Annals_Oncology
doi.org/10.1016/j.an...
🔎 ESMO mCRC Living Guideline
👉Fruquintinib recommended
👉Cetuximab–adagrasib recommended in mKRAS G12C
👉Panitumumab–sotorasib not yet approved
@myESMO
Efficacy of Upfront Panitumumab Plus Intensified Chemo Falls Short in Liver-Limited, Unresectable mCRC @myesmo.bsky.social #ESMOGI25 #oncology #crcsm www.onclive.com/view/efficac...
Efficacy of Upfront Panitumumab Plus Intensified Chemo Falls Short in Liver-Limited, Unresectable mCRC
Panitumumab plus FOLFIRINOX or mFOLFOX6 did not elicit meaningful responses in previously untreated, liver-limited, RAS/BRAF wild-type unresectable mCRC.
www.onclive.com
July 7, 2025 at 8:45 PM
Efficacy of Upfront Panitumumab Plus Intensified Chemo Falls Short in Liver-Limited, Unresectable mCRC @myesmo.bsky.social #ESMOGI25 #oncology #crcsm www.onclive.com/view/efficac...
The FDA has approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer. This combo therapy tackles a previously ‘undruggable’ mutation, offering new hope for advanced cases. A major milestone in precision oncology! 🧬✨ #CancerResearch #OncologyNews
FDA Approves Sotorasib With Panitumumab for <em>KRAS</em> G12C–Mutated Colorectal Cancer
On January 16, the FDA approved a KRAS G12C inhibitor in combination with a monoclonal antibody for adult patients with KRAS G12C–mutated metastatic colorectal cancer, as determined by an FDA-approved...
ascopost.com
January 18, 2025 at 10:07 PM
The FDA has approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer. This combo therapy tackles a previously ‘undruggable’ mutation, offering new hope for advanced cases. A major milestone in precision oncology! 🧬✨ #CancerResearch #OncologyNews
Neo-adjuvantFOLFOX+/- #panitumumab for pts with KRAS-wt locally advanced #coloncancer: FOxTROT Trial www.annalsofoncology.org/article/S092... ➡️ @jenseligmann.bsky.social #GIonc @oncoalert.bsky.social
👉⬇️recurrence 12% vs 21%(HR=0.51,p0.09),significant in EREG/AREG ⬆️
👉⬆️TOX G3 diarrhoea and rash
👉⬇️recurrence 12% vs 21%(HR=0.51,p0.09),significant in EREG/AREG ⬆️
👉⬆️TOX G3 diarrhoea and rash
January 12, 2025 at 4:08 PM
Neo-adjuvantFOLFOX+/- #panitumumab for pts with KRAS-wt locally advanced #coloncancer: FOxTROT Trial www.annalsofoncology.org/article/S092... ➡️ @jenseligmann.bsky.social #GIonc @oncoalert.bsky.social
👉⬇️recurrence 12% vs 21%(HR=0.51,p0.09),significant in EREG/AREG ⬆️
👉⬆️TOX G3 diarrhoea and rash
👉⬇️recurrence 12% vs 21%(HR=0.51,p0.09),significant in EREG/AREG ⬆️
👉⬆️TOX G3 diarrhoea and rash
This report describes a case of bilateral cicatricial ectropion with exposure keratopathy occurring 2 weeks after initiating panitumumab therapy for metastatic colorectal cancer.
bit.ly/cjo_panitumu...
#Ophthalmology #Panitumumab #CicatricialEctropion
bit.ly/cjo_panitumu...
#Ophthalmology #Panitumumab #CicatricialEctropion
A severe case of panitumumab-associated cicatricial ectropion and periorbital dermatitis
Panitumumab is a fully human recombinant monoclonal antibody.1 It targets the epidermal
growth factor receptor (EGFR), which can drive the development and progression of
various solid cancers, includi...
bit.ly
September 24, 2026 at 11:47 AM
This report describes a case of bilateral cicatricial ectropion with exposure keratopathy occurring 2 weeks after initiating panitumumab therapy for metastatic colorectal cancer.
bit.ly/cjo_panitumu...
#Ophthalmology #Panitumumab #CicatricialEctropion
bit.ly/cjo_panitumu...
#Ophthalmology #Panitumumab #CicatricialEctropion
🔴Online today: Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic #colorectalcancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
thelancet.com/journals/lan...
thelancet.com/journals/lan...
August 12, 2025 at 3:41 PM
🔴Online today: Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic #colorectalcancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
thelancet.com/journals/lan...
thelancet.com/journals/lan...
@PavlosMsaouel @UTMDAnderson w well done investigator initiated study leveraging EGFR expression in #renalmedullary — panitumumab & Abraxane. Very important life work for a rare cancer.
@ASCO #ASCO26 @OncoAlert @urotoday
@ASCO #ASCO26 @OncoAlert @urotoday
June 1, 2026 at 2:27 PM
@PavlosMsaouel @UTMDAnderson w well done investigator initiated study leveraging EGFR expression in #renalmedullary — panitumumab & Abraxane. Very important life work for a rare cancer.
@ASCO #ASCO26 @OncoAlert @urotoday
@ASCO #ASCO26 @OncoAlert @urotoday
In Middle-earth terms, sotorasib with panitumumab is like the reforging of Andúril—created to conquer what was thought invincible. KRAS mutations, like Sauron, seemed unstoppable, but this combination cuts through the darkness, bringing hope to advanced colorectal cancer patients. ⚔️✨ #Oncology
January 18, 2025 at 10:07 PM
In Middle-earth terms, sotorasib with panitumumab is like the reforging of Andúril—created to conquer what was thought invincible. KRAS mutations, like Sauron, seemed unstoppable, but this combination cuts through the darkness, bringing hope to advanced colorectal cancer patients. ⚔️✨ #Oncology
Delighted to be sharing some work we have been working on for sometime:
Cetuximab Vs Pantitumumab - we found no efficacy difference but did find different side effect profile. Presenting at #ESMOGI25 this week
doi.org/10.6084/m9.f...
I'll be near the poster Friday PM if anyone wants to talk
Cetuximab Vs Pantitumumab - we found no efficacy difference but did find different side effect profile. Presenting at #ESMOGI25 this week
doi.org/10.6084/m9.f...
I'll be near the poster Friday PM if anyone wants to talk
July 2, 2025 at 10:30 AM
Delighted to be sharing some work we have been working on for sometime:
Cetuximab Vs Pantitumumab - we found no efficacy difference but did find different side effect profile. Presenting at #ESMOGI25 this week
doi.org/10.6084/m9.f...
I'll be near the poster Friday PM if anyone wants to talk
Cetuximab Vs Pantitumumab - we found no efficacy difference but did find different side effect profile. Presenting at #ESMOGI25 this week
doi.org/10.6084/m9.f...
I'll be near the poster Friday PM if anyone wants to talk
PROCC: a predictive score to identify KRAS wild type metastatic colorectal cancer patients who are likely to benefit from panitumumab treatment https://www.medrxiv.org/content/10.1101/2024.12.18.24319211v1
December 22, 2024 at 11:28 AM
PROCC: a predictive score to identify KRAS wild type metastatic colorectal cancer patients who are likely to benefit from panitumumab treatment https://www.medrxiv.org/content/10.1101/2024.12.18.24319211v1
Easier to post a screenshot than going through the link.
@fda.gov approved Sotorasib in combination with panitumumab for KRAS G12C chemorefractory metastatic #colorectalcancer patients based on these results from Code BreaK 300.
Link to @nejm.org publication: www.nejm.org/doi/full/10.... #GI25
@fda.gov approved Sotorasib in combination with panitumumab for KRAS G12C chemorefractory metastatic #colorectalcancer patients based on these results from Code BreaK 300.
Link to @nejm.org publication: www.nejm.org/doi/full/10.... #GI25
January 17, 2025 at 8:14 PM
Easier to post a screenshot than going through the link.
@fda.gov approved Sotorasib in combination with panitumumab for KRAS G12C chemorefractory metastatic #colorectalcancer patients based on these results from Code BreaK 300.
Link to @nejm.org publication: www.nejm.org/doi/full/10.... #GI25
@fda.gov approved Sotorasib in combination with panitumumab for KRAS G12C chemorefractory metastatic #colorectalcancer patients based on these results from Code BreaK 300.
Link to @nejm.org publication: www.nejm.org/doi/full/10.... #GI25
Im Falle von Cetuximab und Panitumumab gibt es eine Assoziation zwischen einem akneähnlichen Ausschlag und dem Ansprechen. Hier: www.leitlinienprogramm-onkologie.de/fileadmin/us...
October 18, 2023 at 2:13 PM
Im Falle von Cetuximab und Panitumumab gibt es eine Assoziation zwischen einem akneähnlichen Ausschlag und dem Ansprechen. Hier: www.leitlinienprogramm-onkologie.de/fileadmin/us...
Sotorasib/Panitumumab Resistance May Be Linked to Genomic Alterations in KRAS G12C+ mCRC @ascocancer.bsky.social #ASCO25 #crcsm #oncology www.onclive.com/view/sotoras...
Sotorasib/Panitumumab Resistance May Be Linked to Genomic Alterations in KRAS G12C+ mCRC
Treatment resistance to sotorasib plus panitumumab may stem from genomic alterations in KRAS G12C–mutated CRC.
www.onclive.com
May 31, 2025 at 4:31 PM
Sotorasib/Panitumumab Resistance May Be Linked to Genomic Alterations in KRAS G12C+ mCRC @ascocancer.bsky.social #ASCO25 #crcsm #oncology www.onclive.com/view/sotoras...
📍 The combo of panitumumab (anti-EGFR antibody) + carboplatin/paclitaxel achieved a 30.2% pCR/RCB-I rate, a 6x improvement over historical controls (5%) 💊
📍 Key Highlights
✅ Targeted EGFR pathway to overcome chemo resistance
#Onco404 #Cancer #Oncology #oncsky #medsky #ClinicalTrials #AACR #EGFR
📍 Key Highlights
✅ Targeted EGFR pathway to overcome chemo resistance
#Onco404 #Cancer #Oncology #oncsky #medsky #ClinicalTrials #AACR #EGFR
April 1, 2025 at 4:07 PM
Abstract 3512: TRIPLETE (bit.ly/4kiMGnt). First-line treatment with modified FOLFOXIRI plus panitumumab improved OS over standard FOLFOX plus panitumumab in patients with unresectable, RAS/BRAF wild-type mCRC. #ASCO25 #gicsm
Program Guide – ASCO Meeting Program Guide
bit.ly
May 29, 2025 at 1:40 PM
Abstract 3512: TRIPLETE (bit.ly/4kiMGnt). First-line treatment with modified FOLFOXIRI plus panitumumab improved OS over standard FOLFOX plus panitumumab in patients with unresectable, RAS/BRAF wild-type mCRC. #ASCO25 #gicsm
Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study. www.esmoopen.com/article/S205... #hvhebron #onco [Text complet]
Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study
In the phase III CodeBreaK 300 trial (NCT05198934), the combination of sotorasib,
a KRASG12C inhibitor, and panitumumab improved clinical outcomes in patients with
chemorefractory KRAS G12C-mutated me...
www.esmoopen.com
August 27, 2026 at 6:17 PM
Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study. www.esmoopen.com/article/S205... #hvhebron #onco [Text complet]
BREAKING 📢: @fda.gov Approves Sotorasib Plus Panitumumab for KRAS G12C–Mutated Colorectal Cancer #crcsm #oncology onclive.com/view/fda-app...
January 16, 2025 at 11:28 PM
BREAKING 📢: @fda.gov Approves Sotorasib Plus Panitumumab for KRAS G12C–Mutated Colorectal Cancer #crcsm #oncology onclive.com/view/fda-app...
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer
ascopubs.org/doi/full/10....
ascopubs.org/doi/full/10....
April 18, 2025 at 10:00 AM
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer
ascopubs.org/doi/full/10....
ascopubs.org/doi/full/10....